The Fragmentation Tax: Unifying the Oncology Pipeline from Enrollment to Adjudication

In oncology research, operational friction usually gets blamed on the protocol. The designs are complex and often site-unfriendly, and that is real. But the protocol is only the starting point. The harder, quieter problem is what happens to the data after a patient is enrolled, when high-resolution imaging has to be captured, RECIST criteria calculated correctly, and serious adverse events reported inside tight windows, all at once, all on the clock. Because centralized imaging reads underpin the efficacy endpoints, the entire trial moves at the speed of its data. When the data slows, the trial slows, and there is no amount of scientific elegance that buys those weeks back.

What makes oncology data slow is rarely a single broken system. It is the space between systems. Enrollment platforms do not talk to document collection. Document collection does not talk to imaging workflows. Imaging does not talk to adjudication. Each tool may work well on its own, but the trial does not run inside any one of them. It runs across all of them, and every boundary between them is a place where data waits, gets re-entered, or gets lost. This is the fragmentation tax. It does not appear as a line item. It appears as delay, and most teams have stopped noticing they are paying it.

The reality of portal fatigue and the rolling crunch

The standard response to a system that cannot do everything is to add another system that does the missing part. Over a few years, that logic produces a stack of portals, each solving one problem and collectively creating a new one. For the people at the site, a single day of study operations now means documenting a milestone in one platform, gathering and redacting source documents in another, entering data into a third, and uploading imaging to a fourth, each with its own login, its own quirks, and its own queue.

This is portal fatigue, and it is not a complaint about software preferences. It is a structural drag on data quality and speed. Every system a coordinator hops between is a chance for a value entered in one place to mismatch a value in another, a chance for a query to sit unanswered because it lives in a tool no one opened today, and a chance for a document to be the right version in one portal and the wrong version in the next. The work of reconciling all of it falls on the people who should be focused on the patient in front of them.

Oncology compresses this further because the timelines never pause. Sites are under relentless, rolling pressure to enter data, clear queries, and submit documentation, and the patients are often acutely ill, which shrinks the window in which any of it can happen. The result is a permanent crunch. Every day becomes a race against the clock, and the clock is not measuring effort. It is measuring how long your endpoint data takes to become usable.

Where the tax compounds: at the review committee

The fragmentation tax is most expensive at the point where it is least visible, which is adjudication. By the time an event reaches an endpoint review committee, the relevant information has been scattered across the same disconnected systems the site has been fighting all along. The patient history is in one place, the redacted source documents in another, the imaging in a third. Someone has to assemble a complete, blinded package by pulling from each, and any gap sends the reviewers back to request more, stalling the read.

For a sponsor, this is where data velocity turns into endpoint risk. A trial whose adjudication keeps stalling is a trial whose primary endpoint keeps slipping, and a review process held together by manual handoffs is harder to defend when an auditor asks how the package was assembled and whether blinding held throughout. For a CRO running this across many sites and many clients, the problem multiplies into a different version of the same stall at every site, with no single place to see where the time is going. In both cases, the cost is the same: decisions that should take days take weeks, and the timeline everyone committed to quietly becomes the timeline no one can hit.

Creating a continuous data pipeline

Operational efficiency in oncology does not come from adding another portal or asking sites to try harder. It comes from removing the boundaries between systems so that data flows from one stage to the next without a manual handoff in between. When enrollment, document and imaging workflows, and adjudication are connected rather than bridged by people, the fragmentation tax simply stops being charged.

In practice, that means a patient identified and qualified at enrollment carries forward into a single, secure document and imaging workflow, so the same source records and reads that the site captures are the ones the review committee sees, without anyone rebuilding the package by hand. Reviewers open one workspace that already holds the patient history, the redacted documents, and the imaging together, blinded and complete. The adjudication that used to wait on assembly can begin immediately, and the audit trail is intact because the data never left a connected environment to get there. The Sequence Platform was built to make this one pipeline rather than four, but the point is not the architecture. The point is what the architecture removes: the logins, the re-entry, the version mismatches, and the weeks of waiting that none of them were ever supposed to cost.

Defensible endpoints start with a connected pipeline

The teams that pull ahead in oncology are not the ones with the most tools. They are the ones who have stopped paying the fragmentation tax. When the pipeline is continuous, site staff get their time back for patient care, data quality improves because there are fewer seams for it to fall through, and endpoints arrive on a timeline you can actually defend. The science still has to be right. But the science only matters if the data behind it can move, hold up, and be trusted. That starts with connecting the pipeline from the first patient enrolled to the final endpoint adjudicated.

See how a unified oncology pipeline connects enrollment through adjudication.